Inhibition of skeletal muscle sodium currents by mexiletine analogues: Specific hydrophobic interactions rather than lipophilia per se account for drug therapeutic profile

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 367, Issue 3, 2003, Pages 318-327

  De Luca, Annamaria ^a   Talon, Sophie ^a   De Bellis, Michela ^a   Desaphy, Jean François ^a   Franchini, Carlo ^a   Lentini, Giovanni ^a   Catalano, Alessia ^a   Corbo, Filomena ^a   Tortorella, Vincenzo ^a   Conte Camerino, Diana ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Lipophilicity; Mexiletine analogues; Skeletal muscle fibers; Sodium channel; Stereoselectivity; Use dependent block; Vaseline gap voltage clamp

Indexed keywords

2 (4 CHLORO 2,6 DIMETHYLPHENOXY) 1 PHENYLETHANAMINE; 2 [(2,6 DIMETHYLPHENYL)THIO] 1 PHENYLETHANAMINE; 3 (4 CHLORO 2,6 DIMETHYLPHENOXY) 2 METHYLPROPAN 1 AMINE; 3 [(2,6 DIMETHYLPHENYL)THIO] 2 METHYLPROPAN 1 AMINE; MEXILETINE; SODIUM CHANNEL BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; FROG; HYDROPHOBICITY; LIPOPHILICITY; NONHUMAN; SKELETAL MUSCLE; SODIUM CURRENT; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANIMALS; HYDROPHOBICITY; MEMBRANE POTENTIALS; MEXILETINE; MUSCLE FIBERS; MUSCLE, SKELETAL; PATCH-CLAMP TECHNIQUES; RANA ESCULENTA; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 12444292787     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-002-0669-0     Document Type: Article

References (35)

1. Andrews P (1986) Functional groups, drug-receptor interactions and drug design. Trends Pharmacol Sci 7:148-151
2. Brown ML, Brown GB, Brouillette WJ (1997) Effects of log P and phenyl ring conformation on the binding of 5-phenylhydantoins to the voltage-dependent sodium channel. J Med Chem 40:602-607
3. Brown ML, Zha CC, Van Dyke CC, Brown GB, Brouillette WJ (1999) Comparative molecular field analysis of hydantoin binding to the neuronal voltage-dependent sodium channel. J Med Chem 42:1537-1545
4. Cannon SC (2001) Voltage-gated ion channelopathies of the nervous system. Clin Neurosci Res 57:772-779
5. + channels: local anesthetics, antiarrhythmics and anticonvulsants. Trends Pharmacol Sci 8:57-65
6. Christopoulos A (1998) Assessing the distribution of parameters in models of ligand-receptor interaction: to log or not to log. Trends Pharmacol Sci 19:351-357
7. Courtney KR (1990) Sodium channel blockers: the size/solubility hypothesis revisited. Mol Pharmacol 37:855-859
8. De Luca A, Natuzzi F, Lentini G, Franchini C, Tortorella V, Conte Camerino D (1995) Stereoselective effects of mexiletine enantiomers on sodium currents and excitability characteristics of adult skeletal muscle fibers. Naunyn-Schmiedebergs Arch Pharmacol 352:653-661
9. De Luca A, Natuzzi F, Falcone G, Duranti A, Lentini G, Franchini C, Tortorella V, Conte Camerino D (1997a) Inhibition of frog skeletal muscle sodium channels by newly synthesized chiral derivatives of mexiletine and tocainide. Naunyn-Schmiedebergs Arch Pharmacol 356:777-787
10. De Luca A, Pierno S, Natuzzi F, Franchini C, Duranti A, Lentini G, Tortorella V, Jockusch H, Conte Camerino D (1997b) Evaluation of the antimyotonic activity of mexiletine and some new analogs on sodium currents of single muscle fibers and on the abnormal excitability of the myotonic ADR mouse. J Pharmacol Exp Ther 282:93-100
11. De Luca A, Natuzzi F, Desaphy J-F, Loni G, Lentini G, Franchini C, Tortorella V, Conte Camerino D (2000) Molecular determinants of mexiletine structure for potent and use-dependent block of skeletal muscle sodium channels. Mol Pharmacol 57:268-277
12. Desaphy J-F, De Luca A, Tortorella P, De Vito D, George AL, Conte Camerino D (2001) Gating of myotonic Na channel mutants defines the response to mexiletine and a potent derivative. Neurology 57:1849-1857
13. Duranti A, Franchini C, Lentini G, Loiodice F, Tortorella V, De Luca A, Pierno S, Conte Camerino D (2000) Homologation of mexiletine alkyl chain and stereoselective blockade of skeletal muscle sodium channels. Eur J Med Chem 35:147-156
14. + channels with increased potency and improved use-dependent activity. J Med Chem 43:3792-3798
15. French RJ, Zamponi GW, Sierralta IE (1998) Molecular and kinetic determinants of local anaesthetic action on sodium channels. Toxicol Lett 100-101:247-254
16. Hille B (1977) Local anesthetics: hydrophylic and hydrophobic pathways for the drug-receptor interaction. J Gen Physiol 69:497-515
17. Hille B, Campbell DT (1976) An improved vaseline-gap voltage-clamp for skeletal muscle fibers. J Gen Physiol 67:265-293
18. Jurkat-Rott K, Lehmann-Horn F (2001) Human muscle voltage-gated ion channels and hereditary disease. Curr Opin Pharmacol 1:280-287
19. Klein CD, Tabeteh GF, Laguna AV, Holzgrabe U, Mohr K (2001) Lipophilicity and membrane interactions of cationic-amphiphilic compounds: syntheses and structure-property relationships. Eur J Pharm Sci 14:167-175
20. + current by diphenhydramine and other diphenyl compounds: molecular determinants of selective binding to the inactivated channels. Mol Pharmacol 57:135-143
21. Kwiecinski H, Ryniewicz B, Ostrzycki A (1992) Treatment of myotonia with antiarrhythmic drugs. Acta Neurol Scand 86:371-375
22. Lee PJ, Sunami A, Fozzard HA (2001) Cardiac-specific external paths for lidocaine, defined by isoform-specific residues, accelerate recovery from use-dependent block. Circ Res 89:1014-1021
23. Li HL, Gaule A, Meadows A, Ragsdale DS (1999) A molecular basis for different local anesthetic affinities of resting versus open and inactivated states of the sodium channels. Mol Pharmacol 55:134-141
24. Liu L, Wendt DJ, Grant AO (1994) Relationship between structure and sodium channel blockade by lidocaine and its amino-alkyl derivatives. J Cardiovasc Pharmacol 24:803-812
25. 3- complexed aromatic fluoride. J Org Chem 64:3373-3375
26. + channels modulate binding affinity and stereoselectivity of local anesthetic enantiomers. Mol Pharmacol 56:404-413
27. Ptácek L (1998) The familial periodic paralyses and nondystrophic myotonias. Am J Med 104:58-70
28. + channels by local anesthetics. Science 265:1724-1728
29. + channels. Proc Natl Acad Sci USA 93:9270-9275
30. Rüdel R, Lehmann-Hom F, Ricker K (1994) The non-dystrophic myotonias. In: Engel AG, Franzini-Armstrong C (eds) Myology. McGraw-Hill, New York, pp 1291-1302
31. Sheldon RS, Hill RJ, Touis M, Wilson LM (1991) Aminoalkyl structural requirements for interaction of lidocaine with class I antiarrhythmic drug receptor on rat cardiac myocytes. Mol Pharmacol 39:609-614
32. + channels enhancing the antimyotonic activity in vivo. Br J Pharmacol 134:1523-1531
33. + channel D3-S6 segment modulates both batrachotoxin and local anesthetic affinities. Biophys J 79:1379-1387
34. + channel D2-S6 residues in batrachotoxin and local anesthetic action. Mol Pharmacol 59:1100-1107
35. + channel α subunit. J Biol Chem 276:20-27